Filing Flows › GeneDx Holdings (WGS) › Capital expenditures
GeneDx Holdings (WGS) capital expenditures by quarter
GeneDx Holdings' capital expenditures were $6.2M in Q3 2025 (third quarter 2025), +161% from Q2 2025. Over the last 3 quarters it ranged from $2.4M (Q2 2025) to $6.2M (Q3 2025).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2025 | $6.2M | +161% | — |
| Q2 2025 | $2.4M | -61% | — |
| Q1 2025 | $6.1M | — | — |
Q3 2025 at a glance
GeneDx Holdings, Q3 2025: revenue $117M (+52% year over year), operating margin -2.8%, net loss $7.6M, operating cash flow $15.8M. The chart follows the revenue to costs, profit and cash.
Questions
What is GeneDx Holdings' capital expenditures?
GeneDx Holdings' capital expenditures were $6.2M in Q3 2025 (third quarter 2025), +161% from Q2 2025.
How has GeneDx Holdings' capital expenditures changed?
Over the last 3 quarters it ranged from $2.4M (Q2 2025) to $6.2M (Q3 2025).